Alcon (SWX:ALC) just picked up U.S. FDA approval for its BRYTLY redness reliever eye drops, a new over the counter product that extends its consumer eye care line.
The FDA news landed alongside a pickup in momentum for Alcon's shares, with a 30-day share price return of 8.01% and a 90-day gain of 6.10% from a recent trough, even though the year-to-date share price return is still down 7.52% and the 5-year total shareholder return has declined 23.64%. This signals that investors are reassessing the business as new products like BRYTLY reach the market.
Scan beyond Alcon and spot other eye care and healthcare names gaining traction with our curated 130 healthcare AI stocks as clinical tech and consumer demand continue to reshape the sector.
The question now is whether Alcon's recent bounce reflects investors finally pricing in the underlying business strength, or if sentiment just swung too far from pessimism. The valuation work starts at this point.
Most Popular Narrative: 32% Undervalued
Alcon's most followed valuation story pegs fair value at CHF85.93 versus the last close at CHF58.76. This highlights a wide gap between what the market currently pays and what that narrative considers the business to be worth using a 4.53% discount rate.
The efficiency program targeting US$100 million in annual run rate savings, combined with tariff refunds that are being selectively reinvested, provides further room for operating margin expansion and higher free cash flow conversion than current expectations assume.
See why 3 investors see Alcon as 32% undervalued .
Result: Fair Value of CHF85.93 (UNDERVALUED)
Still, the bullish Alcon narrative depends on cataract procedure bottlenecks easing and the glaucoma portfolio stabilising, and either factor could easily move the story off course.
Find out about the key risks to this Alcon narrative .
Another View: What Alcon's P/E Is Saying
The bullish Alcon story leans on a CHF85.93 fair value, yet the current P/E of 53.5x tells a different story. That multiple is almost double the European Medical Equipment average of 28.8x and above an estimated fair ratio of 40.8x, which points to valuation risk rather than a clear bargain. Which signal do you weigh more heavily?
See what the numbers say about this price in our valuation breakdown, then stress test it against your own assumptions before acting See what the numbers say about this price — find out in our valuation breakdown. .
For a clearer view of how Alcon's P/E compares with sector peers, take a close look at the relative valuation snapshot
.
Next Steps
Sentiment on Alcon is clearly split, so move quickly to pull up the full data, then weigh the upside against the concerns and decide where you stand with 3 key rewards and 2 important warning signs .
Looking for more investment ideas beyond Alcon?
If Alcon has you rethinking your watchlist, do not stop there. Use the same data driven approach to widen your opportunity set before the market moves.
-
Target potential mispricings by scanning a focused 195 high quality undervalued stocks that filters for quality businesses trading below their estimated worth.
-
Anchor your portfolio with income ideas by reviewing a curated group of 228 dividend fortresses that emphasise higher yields and resilience.
-
Dial down portfolio stress by searching for 228 resilient stocks with low risk scores that pair healthier balance sheets with more measured volatility.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALC.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
